Compare NextEra Energy, Inc. (NEE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? NextEra Energy, Inc. trades at $82.99 (market cap $174.87B), while State Street SPDR S&P Biotech ETF trades at $159.8. The key difference: NextEra Energy, Inc. pays a 2.97% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, NextEra Energy, Inc. nearer its low. Which is the better fit depends on your goals.
| NEE | XBI | |
|---|---|---|
Market Cap | $174.87B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $97.88 | $169.55 |
52-Week Low | $69.83 | $93.43 |
Enterprise Value | $282.20B | — |
Dividend Yield | 2.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $83.83, up 0.48% with a bearish technical signal despite strong analyst support. The company shows solid fundamentals with Q1 and Q2 2026 earnings beats, a 32.4% net income margin, and recent positive developments including a $1.9 billion DOE loan for nuclear plant restart. Cash flow improved to $1.6B net in 2025, though debt-to-asset ratio rose to 47.6%.
Outlook remains positive with 66.7% analyst buy ratings and a $100.20 consensus price target offering 19.5% upside. Key risks include rising leverage, competitive pressures, and execution of growth projects. The stock presents a growth opportunity in renewable energy with institutional backing, balanced by macroeconomic and regulatory uncertainties.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
